Your premier partner in MPN preclinical research
Who we are
Founded in Switzerland as a spinoff of the University of Basel, we offer comprehensive in vivo efficacy studies for MPN, tailored to meet the unique needs of pharmaceutical companies worldwide.
With a focus on Myeloproliferative Neoplasms (MPN), we provide cutting-edge research solutions to accelerate the development of novel therapeutics.
Our commitment to excellence is rooted in scientific rigor, innovation, and a deep understanding of the complexities of MPN preclinical research.
Marc Usart, PhD
Co-founder and CEO
With previous roles in hematology at ETH Zurich and Harvard University, he specialized in MPN research under the mentorship of Prof. Skoda in Basel, Switzerland, where he gained over 5 years of experience managing in vivo drug testing projects in MPN.
Prof. Radek Skoda, MD
Co-founder and board member
With his groundbreaking discovery of the JAK2-V617F mutation and numerous contributions that have significantly advanced our understanding of MPN biology, he stands as a leading scientist in the field. His expertise extends beyond academia to include impactful collaborations within the industry. He is currently leading a research group at Baylor College of Medicine in Houston, TX.